Dermatologic side effects induced by new angiogenesis inhibitors;Effets indésirables dermatologiques des thérapies ciblées antiangiogéniques

Bulletin du Cancer

Volumn 98, Issue 10, 2011, Pages 1221-1229

  Sibaud, Vincent ^a   Garrido Stowhas, Ignacio ^a   Cottura, Ewa ^a   Chevreau, Christine ^a  

^a INSTITUT CLAUDIUS REGAUD   (France)

Author keywords

Angiogenesis inhibitors; Cutaneous adverse events; mTOR inhibitors; Pazopanib; Sorafenib; Vandetanib

Indexed keywords

BEVACIZUMAB; EVEROLIMUS; PAZOPANIB; SORAFENIB; SUNITINIB; TEMSIROLIMUS; VANDETANIB;

ANTIANGIOGENIC THERAPY; CANCER CHEMOTHERAPY; HUMAN; REVIEW; SKIN DISEASE;

EID: 80755175261     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: 10.1684/bdc.2011.1457     Document Type: Review

References (54)

1. Nguyen A, Hoang V, Laguer V, Kelly KM. Angiogenesis in cutaneous disease: part I. J Am Acad Dermatol 2009; 61 : 921-42.
2. Lee WJ, Lee JL, Chang SE, et al. Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib. Br J Dermatol 2009; 161 : 1045-51.
3. Robert C, Mateus C, Spatz A, Wechsler J, Escudier B. Dermatologic symptoms associated with the multikinase inhibitor sorafenib. J Am Acad Dermatol 2009; 60 : 299-305.
4. Rosenbaum SE, Wu S, Newman MA, West DP, Kuzel T, Lacouture ME. Dermatological reactions to the multitargeted tyrosine kinase inhibitor sunitinib. Support Care Cancer 2008; 16 : 557-66.
5. Chu D, Lacouture M, Weiner E, Wu S. Risk of hand-foot skin reaction with the multitargeted kinase inhibitor suitinib in patients with renal cell and non-renal cell carcinoma: a meta-analysis. Clin Genitourin Cancer 2009; 7 : 11-9.
6. Lipworth AD, Robert C, Zhu AX. Hand-foot syndrome (hand-foot skin reaction, palmar-plantar erythrodysesthesia): focus on sorafenib and sunitinib. Oncology 2009; 77 : 257-71.
7. Webster-Gandy JD, How C, Harrold K. Palmar-plantar erythrodysesthesia (PPE): a literature review with commentary on experience in a cancer centre. Eur J Oncol Nurs 2007; 11 : 238-46.
8. Van Moos R, Thuerlimann BJK, Aapro M, et al. Pegylated liposomal doxorubicin-associated hand-foot syndrome: recommendations of an international panel of experts. Eur J Cancer 2008; 44 : 781-90.
9. Deslandres M, Sibaud V, Chevreau C, Delord JP. Cutaneous side effects associated with epidermal growth factor receptor and tyrosine kinase inhibitors. Ann Dermatol Venereol 2008; 1 : 16-24. (Pubitemid 351620943)
10. Yang CH, Lin WC, Chuang CK, et al. Hand-foot skin reaction in patients treated with sorafenib: a clinicopathological study of cutaneous manifestations due to multitargeted kinase inhibitor therapy. Br J Dermatol 2008; 158 : 592-6. (Pubitemid 351239162)
11. Autier J, Mateus C, Wechsler J, Spatz A, Robert C. Cutaneous side effects of sorafenib and sunitinib. Ann Dermatol Venereol 2008; 135 : 148-53. (Pubitemid 351625321)
12. Robert C, Soria JC, Spatz A, et al. Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol 2005; 6 : 491-500. (Pubitemid 40903630)
13. Lacouture ME, Reilly LM, Gerami P, Guitart J. Hand-Foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib. Ann Oncol 2008; 19 : 1955-61.
14. Hutson TE, Bellmunt J, Porta C, et al. Long-term safety of sorafenib in advanced renal cell carcinoma: follow-up of patients from phase III TARGET. Eur J Cancer 2010; 46 : 2432-40.
15. Sibaud V, Delord J, Chevreau C. Sorafenib-induced hand foot skin reaction: a Koebner phenomenon? Target Oncol 2009; 4 : 307-10.
16. Jain L, Sissung TM, Danesi R, et al. Hypertension and hand-foot skin reactions related to VEGFR2 genotype and improved clinical outcome following bevacizumab and sorafenib. J Exp Clin Cancer Res 2010; 29 : 95.
17. Vincenzi B, Santini D, Russo A, et al. Early skin toxicity as a predictive factor for tumor control in hepatocellular carcinoma patients treated with sorafenib. Oncologist 2010; 15 : 85-92.
18. Azad NS, Aragon-Ching JB, Dahut WL, et al. Hand-foot skin reaction increases with cumulative sorafenib dose and with combination anti-vascular endothelial growth factor therapy. Clin Cancer Res 2009; 15 : 1411-6.
19. Anderson R, Jatoi A, Robert C, Wood LS, Keating KN, Lacouture ME. Search for evidence-based approaches for the prevention and palliation of hand-foot skin reaction (HFSR) caused by the multikinase inhibitors (MKIs). Oncologist 2009; 14 : 291-302.
20. Lacouture ME, Wu S, Robert C, et al. Evolving strategies for the management of hand-foot syndrome skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib. Oncologist 2008; 13 : 1001-11.
21. Sibaud V, Chevreau C. Manifestations dermatologiques des thérapies ciblées antiangiogéniques. In : Sibaud V, Robert C, editors. Manifestations cutanées des thérapies ciblées anticancéreuses : une nouvelle dermatologie. Toulouse : Privat, 2010, p. 41-59.
22. Billemont B, Barete S, Rixe O. Scrotal cutaneous side effects of sunitinib. N Engl J Med 2008; 359 : 975-6.
23. Kong HH, Turner ML. Array of cutaneous adverse effects associated with sorafenib. J Am Acad Dermatol 2009; 61 : 360-1.
24. Hartmann JT, Kanz L. Sunitinib and periodic hair depigmentation due to temporary c-kit inhibition. Arch Dermatol 2008; 144 : 1525-6.
25. Kong HH, Sibaud V, Chanco Turner ML, Fojo T, Hornyak TJ, Chevreau C. Sorafenib-induced eruptive melanocytic lesions. Arch Dermatol 2008; 144 : 820-2. (Pubitemid 351846901)
26. Bennani-Lahlou M, Mateus C, Escudier B, Massard C, Soria JC, Spatz A. Eruptive nevi associated with sorafenib treatment. Ann Dermatol Venereol 2008; 135 : 672-4.
27. Franck N, Barete S, Moguelet P, et al. Spiny follicular hyperkeratosis eruption: a new cutaneous adverse effect of sorafenib. J Clin Oncol 2010; 31 : e640-2.
28. Kong HH, Cowen EW, Azad NS, Dahut W, Gutierrez M, Turner ML. Keratoacanthomas associated with sorafenib therapy. J Am Acad Dermatol 2007; 56 : 171-2.
29. Arnault JP, Wechsler J, Escudier B, et al. Keratoacanthomas and squamous cell carcinomas in patients receiving sorafenib. J Clin Oncol 2009; 27 : 59-61.
30. Robert C, Arnault JP, Mateus C. RAF inhibition and induction of cutaneous squamous cell carcinoma. Curr Opin Oncol 2011; 23 : 177-82.
31. Sideras K, Menefee ME, Burton JK, Erlichman C, Bible KC. Profound hair and skin hypopigmentation in an African American woman treated with the multi-targeted tyrosine kinase inhibitor pazopanib. J Clin Oncol 2010; 28 : e312-3.
32. Bible KC, Suman VJ, Molina JR, et al. Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study. Lancet Oncol 2010; 11 : 962-72.
33. Hurwitz HI, Dowlati A, Saini S, et al. Phase I trial of pazopanib in patients with advanced cancer. Clin Cancer Res 2009; 15 : 4220-7.
34. Sternberg CN, Davis ID, Mardiak J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 2010; 28 : 1061-8.
35. Yang CH, Chuang CK, Hsieh JJ, Chang JWC. Targeted therapy and hand-foot skin reaction in advanced renal cell carcinoma. Expert Opin Drug Saf 2010; 9 : 459-70.
36. Wells Jr. SA, Gosnell JE, Gagel RF, et al. Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Oncol 2010; 28 : 767-72.
37. Kiura K, Nakagawa K, Shinkai T, et al. A randomized, double-blind, phase IIa dose-finding study of vandetanib (ZD6474) in Japanese patients with non-small cell lung cancer. J Thorac Oncol 2008; 3 : 386-93. (Pubitemid 351489479)
38. Chang CH, Chang JWC, Hui CY, Yang CH. Severe photosensitivity reaction to vandetanib. J Clin Oncol 2009; 27 : e114-5.
39. Kong HH, Fine HA, Stern JB, Turner MLC. Cutaneous pigmentation after photosensitivity induced by vandetanib therapy. Arch Dermatol 2009; 145 : 923-5.
40. Robert C. Vandetanib (Zactima®). In : Manifestations dermatologiques des therapies ciblées anticancéreuses, une nouvelle dermatologie. Sibaud V, Robert C. Toulouse : Privat, 2010, p. 39.
41. Mahé E, Morelon E, Lechaton S, et al. Cutaneous adverse events in renal transplant recipients receiving sirolimus-based therapy. Transplantation 2005; 79 : 476-82. (Pubitemid 40280181)
42. Ellard SL, Clemons M, Gelmon KA, et al. Randomized phase II study comparing two schedules of everolimus in patients with recurrent/metastatic breast cancer: NCIC Clinical Trials Group IND163. J Clin Oncol 2009; 27 : 4536-41.
43. Aktins MB, Hidalgo M, Stadler WM, et al. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 2004; 22 : 909-18. (Pubitemid 41103603)
44. Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008; 372 : 449-56.
45. Giaccherro D, Schneider P, Sibaud V. Manifestations dermatologiques des inhibiteurs de mTOR. In : Sibaud V, Robert C, editors. Manifestations cutanées des thérapies ciblées anticancéreuses : une nouvelle dermatologie. Toulouse : Privat, 2010, p. 71-82.
46. Raymond E, Alexandre J, Faivre S, et al. Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer. J Clin Oncol 2004; 22 : 2336-47. (Pubitemid 41115390)
47. O'Donnell A, Faivre S, Burris HA, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors. J Clin Oncol 2008; 26 : 1588-95.
48. Balagula Y, Huston KB, Busam KJ, Lacouture ME, Chapman PE, Myskowski PL. Dermatologic side effects associated with the MEK 1/2 inhibitor selumetinib (AZD6244, ARRY-142886). Invest New Drugs 2011; 29 : 1114-21.
49. Sibaud V, Dalenc F, mourey L, Chevreau C. Paronychia and pyogenic granuloma induced by new anticancer mTOR inhibitors. Acta Dermatol Venereol 2011; 91 : 584-5.
50. Tabernero J, Rojo F, Calvo E, et al. Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors. J Clin Oncol 2008; 26 : 1603-10.
51. Motzer RJ, Hudes GR, Curti BD, et al. Phase I/II trial of temsirolimus combined with interferon alfa for advanced renal cell carcinoma. J Clin Oncol 2007; 25 : 3958-64. (Pubitemid 47477274)
52. Fricain JC, Cellerier K, Sibaud V, Catros S, Taïeb A, Merville P. Oral ulcers in kidney allograph recipients treated with sirolimus. Ann Dermatol Venereol 2008; 11 : 737-41.
53. Escudier B, Pluzanska A, Koralewski P, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007; 370 : 2103-11. (Pubitemid 350296300)
54. Wasif Saif M, Longo WL, Israel G. Correlation between rash and a positive drug response associated with bevacizumab in a patient with advanced colorectal cancer. Clin Colorectal Cancer 2008; 7 : 144-8. (Pubitemid 351518777)